Texas A&M Biologist Joseph Sorg, and his postdoctoral mentor at Tufts University, founded Spordiff Therapeutics in 2017. Spordiff Therapeutics is developing a small molecule to prevent Clostridium difficile (C. diff) antibiotic-associated colitis (AAC). The Spordiff approach will prevent onset of AAC by inhibiting germination of C. diff spores, resulting in a new standard of care.
